Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 7/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.49 |
| ▸ | STK17B | O94768 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104075 | 0.83 | BCL6 (0.63) | BCL6NCOR2STK17ASTK17BSYK | |
| Diethylamine SCHEMBL2105376 | 0.79 | SYK (0.53) | BCL6NCOR2SYKAURKAEGFR | |
| Diethylamine SCHEMBL2101075 | 0.76 | BCL6 (0.43) | BCL6NCOR2SYKAURKAEGFR | |
| SCHEMBL303236 | 0.75 | STK17A (0.62) | BCL6STK17ASTK17BSYKMEN1 | |
| SCHEMBL653915 | 0.74 | SYK (0.50) | BCL6NCOR2STK17ASTK17BSYK | |
| SCHEMBL2104215 | 0.74 | SYK (0.60) | BCL6NCOR2SYKAURKAEGFR | |
| SCHEMBL2103381 | 0.74 | SYK (0.58) | BCL6STK17ASYKAURKAEGFR | |
| SCHEMBL2103244 | 0.73 | SYK (0.67) | BCL6NCOR2SYKAURKAEGFR | |
| SCHEMBL656032 | 0.73 | SYK (0.72) | BCL6STK17ASTK17BSYKAURKA | |
| SCHEMBL2103921 | 0.72 | SYK (0.59) | BCL6NCOR2STK17ASTK17BSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |